Article Information
History
- November 30, 2020.
Article Versions
- You are currently viewing Version 1 of this article (November 30, 2020 - 07:49).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Christian Irsara1,
- Alexander E. Egger1,
- Wolfgang Prokop1,
- Manfred Nairz2,
- Lorin Loacker1,
- Sabina Sahanic2,
- Thomas Sonnweber2,
- Wolfgang Mayer3,
- Harald Schennach3,
- Judith Loeffler-Ragg2,
- Rosa Bellmann-Weiler2,
- Ivan Tancevski2,
- Günter Weiss2,
- Markus Anliker1,
- Andrea Griesmacher1 and
- Gregor Hoermann1,4,*
- 1Central Institute of Clinical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck, Innsbruck, Austria
- 2Department of Internal Medicine II, Infectious Diseases, Pneumology, Rheumatology, Medical University of Innsbruck, Innsbruck, Austria
- 3Central Institute for Blood Transfusion and Immunology (ZIB), University Hospital of Innsbruck, Innsbruck, Austria
- 4MLL Munich Leukemia Laboratory, Munich, Germany
- ↵* Corresponding author; email: gregor.hoermann{at}tirol-kliniken.at
Posted November 30, 2020.
Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay
